RESUMO
Dichloroacetate (DCA) markedly reduces circulating cholesterol levels in animals and in patients with combined hyperlipoproteinemia or homozygous familial hypercholesterolemia (FH). To investigate the mechanism of its cholesterol-lowering action, we studied the effects of DCA and its hepatic metabolites, glyoxylate and oxalate, on the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase) obtained from livers of healthy, reverse light-cycled rats. Oral administration of DCA for 4 d decreased HMG CoA reductase activity 46% at a dose of 50 mg/kg per d, and 82% at a dose of 100 mg/kg per d. A 24% decrease in reductase activity was observed as early as 1 h after a single dose of 50 mg/kg DCA. The inhibitory effect of the drug was due to a fall in both expressed enzyme activity and the total number of reductase molecules present. DCA also decreased reductase activity when added to suspensions of isolated hepatocytes. With chronic administration, DCA inhibited 3H2O incorporation into cholesterol by 38% and into triglycerides by 52%. When liver microsomes were incubated with DCA, the pattern of inhibition of reductase activity was noncompetitive for both HMG CoA (inhibition constant [Ki] 11.8 mM) and NADPH (Ki 11.6 mM). Inhibition by glyoxylate was also noncompetitive for both HMG CoA (Ki 1.2 mM) and NADPH (Ki 2.7 mM). Oxalate inhibited enzyme activity only at nonsaturating concentrations of NADPH (Ki 5.6 mM). Monochloroacetate, glycollate, and ethylene glycol, all of which can form glyoxylate, also inhibited reductase activity. Using solubilized and 60-fold purified HMG CoA reductase, we found that the inhibitory effect of glyoxylate was reversible. Furthermore, the inhibition by glyoxylate was an effect exerted on the reductase itself, rather than on its regulatory enzymes, reductase kinase and reductase phosphatase. We conclude that the cholesterol-lowering effect of DCA is mediated, at least in part, by inhibition of endogenous cholesterol synthesis. The probable mechanisms are by inhibition of expressed reductase activity by DCA per se and by conversion of DCA to an active metabolite, glyoxylate, which noncompetitively inhibits HMG CoA reductase. These studies thus identify a new class of pharmacological agents that may prove useful in regulating cholesterol synthesis and circulating cholesterol levels in man.
Assuntos
Acetatos/farmacologia , Ácido Dicloroacético/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases , Microssomos Hepáticos/enzimologia , Animais , Colesterol/biossíntese , Relação Dose-Resposta a Droga , Glioxilatos/farmacologia , Cinética , Masculino , Oxalatos/farmacologia , Ácido Oxálico , Ratos , Ratos EndogâmicosRESUMO
To investigate the mechanism by which o'p'-DDD (2,2-bis [2-chlorphenyl-4-chlorophenyl]-1,1-dichloroethane; Mitotane) produces hypercholesterolemia in man, we studied the effect of the drug on hepatic 3-hydroxy-3-methylglutaryl-CoA reductase activity in reverse light-cycled rats. o,p'-DDD markedly stimulated reductase activity in vivo and in vitro in a dose-dependent manner. This effect was not associated with demonstrable adrenocortical toxicity or changes in plasma corticosterone concentrations. Thus o,p'-DDD may elevate circulating cholesterol levels in man by increasing endogenous cholesterol synthesis. In addition, the o,p'-DDD may elevate circulating cholesterol levels in man by increasing endogenous cholesterol synthesis. In addition, the o,p'-DDD-treated rat may serve as a useful model for testing other agents for the ability to suppress endogenous cholesterol synthesis and lower circulating cholesterol levels.
Assuntos
Hidroximetilglutaril-CoA Redutases/análise , Fígado/enzimologia , Mitotano/efeitos adversos , Glândulas Suprarrenais/efeitos dos fármacos , Animais , Colesterol/sangue , Corticosterona/sangue , Técnicas In Vitro , Masculino , Ratos , Ratos EndogâmicosRESUMO
Diets high in carbohydrate and low in fat led to a decrease in the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of healthy, reverse light-cycled rats. The effect on reductase was due both to a decline in expressed enzyme activity and to a decrease in total number of enzyme molecules. Inhibition of reductase activity was paralleled by a fall in hepatic cholesterolgenesis and by an increase in triglyceride formation. Thus, a reduction in endogenous cholesterol synthesis may explain the serum cholesterol-lowering effect of high carbohydrate, low fat diets in man.